scholarly journals Markers of myocardial ischemia: pathophysiological substantiation of clinical application

2018 ◽  
pp. 17-25
Author(s):  
Н.П. Лямина ◽  
Э.С. Карпова ◽  
Е.В. Котельникова
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Molecular Markers ◽  
Clinical Practice ◽  
Cardiovascular Diseases ◽  
Myocardial Ischemia ◽  
Early Diagnosis ◽  
Complex Problem ◽  
Ischemic Damage ◽  
Highly Sensitive

Распространенность сердечно-сосудистых заболеваний с проявлениями ишемии диктует необходимость поиска методов, которые позволяют выявлять ишемию на ранних этапах ее развития, что дает возможность более эффективного лечения, корректирования состояния больных и предупреждения возможных осложнений. В современной клинической практике для диагностики ишемической болезни сердца применяется множество методов различных по своей достоверности и информативности. Одним из перспективных методов ранней диагностики ишемической болезни сердца является идентификация биохимических и молекулярных маркеров, которые чувствительны и специфичны для ишемического повреждения миокарда на ранних сроках в отсутствии некроза и повышения маркеров клеточного повреждения кардиомиоцитов. Использование биомаркеров ранней диагностики ишемии является перспективным подходом к решению комплексной задачи безопасного кардиомониторинга больных с различными сердечно-сосудистыми заболеваниями. Благодаря определению достаточно простых, но вместе с этим высокочувствительных и специфичных маркеров ишемии миокарда и кардиопротекции можно значительно повысить эффективность оказания медицинской помощи. Prevalence of cardiovascular diseases with manifestations of ischemia dictates requirement for methods for early detection of ischemia, which provides more effective treatment, correction of patient’s condition, and prevention of possible complications. In modern clinical practice, a variety of methods is used for detection of IHD, which differ in their reliability and informativeness. One of promising methods for early diagnosis of coronary heart disease is identification of biochemical and molecular markers that are sensitive and specific for early ischemic damage of the myocardium in the absence of necrosis and increased markers of cardiomyocyte injury. The use of biomarkers for early diagnosis of ischemia is a promising approach to solving the complex problem of safe cardiomonitoring in patients with different cardiovascular diseases. By identifying rather simple but at the same time highly sensitive and specific markers for myocardial ischemia and cardioprotection, the efficiency of medical care can be significantly improved.

scholarly journals Russian innovations in the treatment of arterial hypertension in clinical practice — a real way to achieve success

2020 ◽  
Vol 96 (7) ◽  
pp. 503-507
Author(s):  
N. Yu. Borovkova
Keyword(s):  
Heart Failure ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Clinical Practice ◽  
Cardiovascular Diseases ◽  
Arterial Hypertension ◽  
Fixed Combination ◽  
Wide Range ◽  
Rational Combination ◽  
Pharmaceutical Plant

The review is devoted to introducing a wide range of internists to the new fixed combination of ramipril and indapamide (Concealar-D24), created by Russian scientists. This is the first original domestic development for the treatment of arterial hypertension, which is successfully produced by the first Russian resident of the special economic zone, the pharmaceutical plant «VERTEX» in St. Petersburg. The advantage of Concealar-D24 is a rational combination of two drugs that have not only antihypertensive and organoprotective effects, but also a large convincing base of research on their impact on the prognosis of life in patients with cardiovascular diseases: arterial hypertension, coronary heart disease, heart failure.

scholarly journals Colchicine in patients with coronary heart disease: new possibilities in reduction of the residual inflammatory risk

2021 ◽  
Vol 6 ◽  
pp. 12-21
Author(s):  
E.S. Eniseeva ◽  
◽  
K.V. Protasov ◽  
Keyword(s):  
Coronary Heart Disease ◽  
Acute Coronary Syndrome ◽  
Heart Disease ◽  
Clinical Practice ◽  
Cardiovascular Diseases ◽  
Cardiovascular Complications ◽  
Coronary Syndrome ◽  
Anti Inflammatory ◽  
Atherosclerotic Cardiovascular Diseases ◽  
Colchicine Application

Inflammation plays an important role in atherosclerotic plaque destabilisation and the development of cardiovascular complications. Suppression of its activity in order to reduce residual inflammatory risk in atherosclerotic cardiovascular diseases remains an urgent and unresolved problem to the date. Over the recent years, evidence of the effectiveness of such an approach in secondary prevention of coronary heart disease has been obtained. The purpose of this review was to analyse modern literature on the effect of anti-inflammatory therapy with colchicine on the prognosis of patients with coronary heart disease. The review was carried out using the search for papers published in the PubMed and ClinicalTrials databases within the period from 2007 to 2021. The search was carried out using the keywords «colchicine», «inflammation», «atherosclerosis», «coronary heart disease» and «acute coronary syndrome». The anti-inflammatory and antiatherogenic effects of colchicine are discussed. The paper presents results of studies devoted to the use of colchicine in chronic and acute coronary syndrome, including the key ones LoDoCo2 (2020) and COLCOT (2019) which provided evidence of the effect of the drug on the disease outcome. The issues of safety and prospects of colchicine application in clinical practice for reduction of the residual inflammatory risk in patients with coronary heart disease are addressed.

scholarly journals The use of scales in clinical practice. Part 1. Coronary heart disease

2017 ◽  
Vol 94 (11) ◽  
pp. 861-864
Author(s):  
Farid I. Belyalov
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Clinical Practice ◽  
Coronary Artery ◽  
Cardiovascular Diseases ◽  
Coronary Artery Diseases

Scores for diagnosis, prediction and treatment cardiovascular diseases are discussed in the article. Advantages and limitations of popular scores for stable coronary artery diseases, acute coronary syndroms and risk of cardiovascular diseases in clinical practice are discussed.

Prediction of atherosclerosis in children and the possibility of early prevention of coronary heart disease

1999 ◽  
Vol 80 (4) ◽  
pp. 296-297
Author(s):  
O. I. Pikuza ◽  
V. N. Oslopov ◽  
H. M. Vakhitov ◽  
A. A. Babushkina ◽  
S. E. Nikolsky
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Coronary Artery ◽  
Cardiovascular Diseases ◽  
Childhood And Adolescence ◽  
Early Prevention ◽  
Cerebrovascular Pathology ◽  
Artery Disease

Cardiovascular diseases caused by atherosclerosis (coronary artery disease, cerebrovascular pathology, etc.) are responsible for 40-50% of all deaths in adults. Of particular concern to clinicians is the emerging unfavorable tendency to "rejuvenate" these diseases. Currently, the fact that atherosclerosis (AS) begins to form in childhood and adolescence is indisputable.

scholarly journals Comparison of Clinical Efficacy of Ticagrelor and Clopidogrel for Treatment of Coronary Heart Disease with Myocardial Ischemia

2019 ◽  
Vol 3 (6) ◽  
Author(s):  
Shuo Huang
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Shear Rate ◽  
Myocardial Ischemia ◽  
Clinical Efficacy ◽  
Control Group ◽  
Study Group ◽  
Clinical Indicators ◽  
Whole Blood Viscosity ◽  
St Segment

Objective: To compare clinical efficacy of ticagrelor and clopidogrel for treatment of coronary heart disease with myocardial ischemia to provide references for later phase of clinical treatment. Methods: Ninety-six coronary heart disease patients with myocardial ischemia admitted to our hospital from July 20 to July 2019 were recruited as subjects. They were randomly divided into study group and control group according to parity of case number, with 48 patients in each group. Control group was given treatment with clopidogrel, while patients in study group were given treatment with ticagrelor. Clinical efficacy was compared between the both groups. Results: Comparison showed that total effective rate of clinical treatment was higher in study group when compared to control group (P<0.05). Frequency of ST segment depression, duration of ST segment depression, systolic blood pressure, diastolic blood pressure, heart rate and other clinical indicators in study group were superior to control group (P<0.05). Whole blood viscosity at low shear rate, whole blood viscosity at high shear rate, plasma viscosity shear rate, total cholesterol, triglyceride and other haemorheological parameters in study group were superior to control group (P<0.05). Conclusion: Application of ticagrelor has higher clinical efficacy than clopidogreal for coronary heart disease patients with myocardial ischemia. Clinical indicators and haemorheological parameters of myocardial ischemia patients were significantly improved. It should be promoted for application.

scholarly journals Prolonged duration of myocardial ischemia in patients with coronary heart disease and impaired cardiopulmonary baroreceptor sensitivity.

Circulation ◽  
1990 ◽  
Vol 81 (6) ◽  
pp. 1792-1802 ◽  
Author(s):  
B Trimarco ◽  
S Chierchia ◽  
G Lembo ◽  
N De Luca ◽  
B Ricciardelli ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Myocardial Ischemia ◽  
Baroreceptor Sensitivity ◽  
Prolonged Duration

Abstract 13769: Assessing the Risk for Cardiovascular Diseases According to Lipoprotein(a) Levels

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Narek A Tmoyan ◽  
Marat V Ezhov ◽  
Olga I Afanasieva ◽  
Uliana V Chubykina ◽  
Elena A Klesareva ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Cardiovascular Diseases ◽  
Carotid Artery ◽  
Lower Extremity ◽  
Carotid Artery Disease ◽  
Lipoprotein A ◽  
Artery Disease ◽  
Lower Extremity Artery Disease

Introduction: There is no common opinion about threshold lipoprotein(a) [Lp(a)] concentration for atherosclerotic cardiovascular diseases (ASCVD) risk. Different clinical guidelines and consensus documents postulated cut-off Lp(a) level as 30 mg/dL or 50 mg/dL. We assessed the concentration of Lp(a) that associated with ASCVD of different locations. Methods: The study included 1224 patients with ASCVD. Lp(a) concentration was measured by enzyme-linked immunosorbent assay in serum. Patients were divided into 3 groups: group I - Lp(a)<30 mg/dL, group II - 30≤Lp(a)<50 mg/dL, group III - Lp(a)≥50 mg/dL (table). Results: Coronary heart disease, carotid artery disease, lower extremity artery disease, myocardial infarction and ischemic stroke were diagnosed in 61%; 34%; 23%; 42% and 11% patients, respectively. Lower extremity artery disease, carotid artery disease and myocardial infarction were more frequent in patients with Lp(a) concentration from 30 to 50 mg/dL compared to patients with Lp(a) <30 mg/dL: 36%, 41%, 48% vs. 17%, 30%, 36% respectively, p<0.01 for all. Subjects with Lp(a) 30-50 mg/dL (n=182, 15%) had a greater odds ratio of lower extremity artery disease, carotid artery disease and myocardial infarction compared to patients with Lp(a) <30 mg/dL (table). ROC analysis demonstrated that Lp(a) cut-off levels for lower extremity artery disease, carotid artery disease, coronary heart disease and myocardial infarction were 26; 21; 37 and 36 mg/dL, respectively. Conclusions: Our results demonstrate that in case of Lp(a) cut-off level of 50 mg/dL about 15% of patients are underestimated for the risk of ASCVD. Lp(a) cut-off level for ASCVD is between 20 and 40 mg/dL regarding the atherosclerosis location.

Sign in / Sign up

Export Citation Format

Share Document